Highlights HilleVax, Inc.

Equities

HLVX

US43157M1027

Real-time Estimate Cboe BZX Other stock markets 10:14:37 2024-05-23 am EDT			5-day change	1st Jan Change
14.02 ^USD	-0.88%		-10.85%	-13.52%

May. 22	Hillevax Insider Sold Shares Worth $266,291, According to a Recent SEC Filing	MT
May. 09	HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
HilleVax Q4 Net Loss Widens; Shares Extend Decline After Hours	Mar. 20	MT
HilleVax, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
HilleVax, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 20	CI
Kanghua Biological Products Licenses Norovirus Vaccine to HilleVax	Jan. 08	MT
HilleVax Q3 Net Loss Widens	Nov. 09	MT
HilleVax, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
HilleVax, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
HilleVax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate	23-04-25	CI
HILLEVAX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-17	AQ
HilleVax, Inc. Appoints Shane Maltbie to Chief Financial Officer	23-01-09	CI
HilleVax Inc. Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate	22-12-05	CI
HILLEVAX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-10	AQ
HilleVax Announces Positive Recommendation from Safety Data Monitoring Committee for NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate	22-08-31	CI
HilleVax Q2 Net Loss Widens	22-08-11	MT
HilleVax : Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Form 8-K	22-08-10	PU
HILLEVAX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-10	AQ
HilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress	22-08-10	GL
Factbox-U.S. IPO activity plunges as Ukraine war triggers volatility	22-08-10	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights HilleVax, Inc.

Equities

HLVX

US43157M1027

Highlights

Filters